In:
Immunity, Inflammation and Disease, Wiley, Vol. 9, No. 2 ( 2021-06), p. 503-511
Abstract:
Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunotherapy with fresh apples (AITA) could be a promising natural treatment of both BPA and prFA. Objective To assess the clinical efficacy of immunotherapy by daily apple consumption for patients with BPA and prFA. Methods A daily defined increasing amount of selected cultivars (Red Moon®, Pink Lady®, Topaz, Golden Delicious) was continuously consumed by 16 patients (12 female; median age; 50; range, 23–68 years), leading to increased intake of allergen over a period of at least 8 months. Specific IgE and IgG 4 to Bet v 1 and Mal d 1, conjunctival and oral provocation tests, skin reactivity, and the average daily rhinoconjunctivitis combined symptom and medication score (CSMS) were measured during the peak birch pollen season. Results After 8 months of therapy, patients showed increased tolerance to apples ( p 〈 .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased ( p 〈 .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% ( p 〈 .001), as did conjunctival reactivity to birch pollen extract by 27% ( p 〈 .01), while specific IgG 4 to Mal d 1 and Bet v 1 increased ( p 〈 .01).
Type of Medium:
Online Resource
ISSN:
2050-4527
,
2050-4527
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2740382-8
Permalink